Christopher D'Andrea, PA-C, is a physician assistant in hematology oncology at Cleveland Clinic Taussig Cancer Center. Primarily managing clinic patients within the lymphoma department, he also provides care on the lymphoma/multiple myeloma and leukemia inpatient services. Additionally, Mr. D’Andrea helps staff the cancer associated thrombosis clinic, and perform and teach bone marrow biopsies. He has presented at conferences on lymphoma including chronic lymphocytic leukemia, as well as participated in local advisory board meetings.
Mr. D’Andrea earned his bachelor’s degree from Ohio State University in psychology and subsequently worked as a behavioral therapist for many years before pursuing a career as a physician assistant. He has been a physician assistant at Cleveland Clinic with the lymphoma team since completing his master’s degree in physician assistant studies at DeSales University in 2014.
Alison Duffy, PharmD, BCOP, is a hematology/oncology clinical pharmacy specialist and associate professor at the University of Maryland School of Pharmacy with a practice site at The University of Maryland Greenebaum Comprehensive Cancer Center within inpatient and outpatient oncology. She serves as PGY2 oncology pharmacy residency program coordinator, and has authored clinical outcomes, practice-based, and educational methods and outcomes-related research. Dr. Duffy has delivered various local, regional, and national oncology related presentations and has served on Hematology Oncology Pharmacy Association (HOPA) committees.
Dr. Duffy graduated from the University of Rhode Island School of Pharmacy and completed her PGY1 pharmacy practice residency and PGY2 hematology/oncology pharmacy residency at University of Cincinnati Health in Cincinnati, Ohio.
Amy Goodrich, RN, MSN, CRNP-AC, is a nurse practitioner in the Hematologic Malignancies Program at The Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland where she manages patients with various types of hematologic malignancies, concentrating on the lymphomas. Goodrich also oversees the Cancer Center’s research nurses and is very involved in research operations. She has presented extensively on hematologic malignancies, new agents, symptom management, and a variety of topics important to oncology nursing.
She earned her undergraduate nursing degree from the University of Pittsburgh and earned her master’s degree from The Johns Hopkins University.
Dr. Hill is the Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute. He received his undergraduate degree from Dartmouth College and earned his Ph.D. in genetics through work done at Cold Spring Harbor Laboratory. He received his medical degree from the University of Chicago Pritzker School of Medicine where he also completed his residency in Internal Medicine. He conducted his hematology/oncology fellowship at the Cleveland Clinic. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma. He is the principal investigator of multiple on-going clinical trials of new cancer treatments including novel cellular therapies. He serves as the Chairman of the Pharmacy & Therapeutics (P&T) Committee within the Department of Hematology and Medical Oncology, co-director of the Lymphoid Malignancies Center of Excellence and serves on the editorial board of several peer reviewed journals. He is Associate Professor of Medicine of the Cleveland Clinic Lerner College of Medicine is an active member of the Case Comprehensive Cancer Center, American Society of Hematology (ASH), National Cancer Institute (NCI) cooperative groups in leukemia and lymphoma, the Center for International Blood and Marrow Transplant Research (CIBMTR) as well as a committee member of the National Comprehensive Cancer Network (NCCN).
Leora Lowenthal, LICSW, OSW-C, MPA, has been working in healthcare for 23 years and currently serves as program leader for hematology & oncology social work at Boston’s Beth Israel Deaconess Medical Center. In addition to her clinical work, she has served on several boards including three years as education director for the Association of Oncology Social Work. She currently serves on the board of directors for the Board of Oncology Social Work Certification and is a member of the Medical Advisory Council for the Cutaneous Lymphoma Foundation.
Ms. Lowenthal holds master's degrees in social work and public administration respectively, and a post-graduate certificate in bioethics and the medical humanities.
Dr. Pagel is a 2019 Seattle Met Top Doctor Award winner. Dr. Pagel is an international hematology expert with a world-class reputation for research and excellence in patient care. He is dedicated to individualized patient care that is based on mutual respect and trust. He is incredibly excited to be a part of the Swedish Cancer Institute. Dr. Pagel feels the work being done here is life-changing for patients and will deliver new advancements in cancer treatment for patients in the Pacific Northwest and beyond. Prior to joining Swedish, Dr. Pagel spent more than a decade as an associate member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center and associate professor in the Medical Oncology Division at the University of Washington.
Dr. Koffman is a well-known doctor, educator, and clinical professor-turned-patient who has dedicated himself to teaching and helping the CLL community since his own CLL diagnosis in 2005. Dr. Koffman believes that his dual roles as a retired physician and patient give him a unique understanding that allows him to provide clear explanations of complex issues, advocate for his fellow patients, and inform his fellow healthcare providers. Besides his medical degree, Dr. Koffman has a master’ degree in medical education. He is a retired family doctor and clinical professor at the Keck School of Medicine.
Dr. Koffman co-founded and serves as the chief medical officer and executive vice president of the nonprofit, CLL Society Inc., and he writes a widely followed blog. Dr. Koffman has shared online and across the world his battle with his leukemia, including a failed bone marrow transplant and successes with two Phase 1 trials, including CAR T-cell therapy.
This project is supported by Pharmacyclics and Janssen Oncology.
